Scarica l'app Stockscreener
16.30
0.76%
0.13
Precedente Chiudi:
$16.17
Aprire:
$16.38
Volume 24 ore:
203.98K
Relative Volume:
0.45
Capitalizzazione di mercato:
$5.81B
Reddito:
$5.21B
Utile/perdita netta:
$-211.00M
Rapporto P/E:
-26.38
EPS:
-0.6179
Flusso di cassa netto:
$861.30K
1 W Prestazione:
+1.96%
1M Prestazione:
-0.16%
6M Prestazione:
-3.24%
1 anno Prestazione:
+13.78%
Intervallo 1D:
$16.24
$16.47
Intervallo di 1 settimana:
$15.74
$16.47
Portata 52W:
$13.09
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Nome
Bausch Lomb Corp
Settore
Industria
Telefono
908-541-5456
Indirizzo
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.30 | 5.77B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
356.05 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
159.34 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.28 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
68.02 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
201.71 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Neutral |
| 2025-05-02 | Reiterato | H.C. Wainwright | Buy |
| 2025-03-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Iniziato | Raymond James | Outperform |
| 2024-05-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Iniziato | Stifel | Hold |
| 2023-10-03 | Ripresa | Evercore ISI | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Iniziato | Needham | Hold |
| 2022-12-21 | Iniziato | Barclays | Equal Weight |
| 2022-09-12 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-06-24 | Iniziato | Evercore ISI | Outperform |
| 2022-06-06 | Iniziato | Citigroup | Buy |
| 2022-05-31 | Iniziato | Deutsche Bank | Hold |
| 2022-05-31 | Iniziato | Goldman | Neutral |
| 2022-05-31 | Iniziato | Guggenheim | Buy |
| 2022-05-31 | Iniziato | JP Morgan | Neutral |
| 2022-05-31 | Iniziato | Jefferies | Buy |
| 2022-05-31 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Iniziato | Wells Fargo | Overweight |
| 2022-05-11 | Iniziato | Cowen | Outperform |
Mostra tutto
Bausch Lomb Corp Borsa (BLCO) Ultime notizie
Bausch + Lomb Corp (BLCO) Balance Sheet - TradingKey
Bausch + Lomb Corp (BLCO) Cash Flow - TradingKey
Bausch + Lomb Corp (BLCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bausch + Lomb Corp (BLCO) Institutional Confidence - TradingKey
BLCO|Bausch + Lomb Corp|Price:16.170|Chg%:+0.210 - TradingKey
Bausch + Lomb Corporation (BLCO) Gets a Hold from Wells Fargo - The Globe and Mail
BLCO Forecast — Price Target — Prediction for 2027 - TradingView
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead - Yahoo Finance
Bausch + Lomb launches EyeGility preloaded IOL delivery system in US - Ophthalmology Times Europe
Bausch + Lomb launches EyeGility inserter for enVista IOLs in the US - MSN
Bausch Health Companies stock hits 52-week low at $4.56 By Investing.com - Investing.com South Africa
Bausch Health Companies stock hits 52-week low at $4.56 - Investing.com
Bausch + Lomb launches EyeGility Inserter to streamline cataract lens delivery in US - Indian Pharma Post
BHC5652799 Bond Profile — Key Metrics - TradingView
Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System - VisionMonday.com
Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Nigeria
Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says - Moomoo
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S. - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing A Potential 11.54% Upside - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail
Bausch + Lomb launches EyeGility IOL delivery system in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb's BL1107 falls short in phase 2 glaucoma trial, redirects program toward geographic atrophy implant - Ophthalmology Times Europe
Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System In The United States - marketscreener.com
Bausch + Lomb launches EyeGility IOL delivery system in U.S. - Investing.com
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States - Business Wire
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $21 - Moomoo
(BLCO) Equity Market Report (BLCO:CA) - Stock Traders Daily
Bausch + Lomb's BL1107 fails primary end point in Phase 2 glaucoma trial - Optometry Times
Ophthalmology Devices Market Report Released, Includes - GlobeNewswire
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others - Yahoo Finance UK
Bausch + Lomb Corporation (BLCO) Stock Analysis: Examining a Healthcare Leader with 11.68% Potential Upside - DirectorsTalk Interviews
(BLCO) Technical Pivots with Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN
Bausch + Lomb ditches BL1107 in glaucoma after trial miss - The Pharma Letter
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - BioSpace
Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates - Yahoo Finance
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform - VisionMonday.com
Bausch + Lomb halts glaucoma eye drop program after trial miss - Investing.com UK
Bausch + Lomb halts glaucoma eye drop program after trial miss By Investing.com - Investing.com South Africa
Bausch + Lomb Ends Glaucoma Eye-Drop Development After Missed Trial Endpoint - Moomoo
Bausch to stop glaucoma eye drop development after trial miss - Reuters
BLCO stock stays supported by diversified eye-health portfolio - Ad-hoc-news.de
Bausch Lomb Corp Azioni (BLCO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.32%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):